Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites


Video Source: http://www.telegraph.co.uk

 

What does Iconocast do? We receive health and science press releases from major research institutes, government agencies, and universities daily. These are articles and press releases that are sent to all publishers regularly. Do we also borrow news from other publishers? Yes, we do and so do many other major Internet publishers such as SeattleTimes.com (from almost all publishers), Washingtonpost.com (from all publishers) and CBS News (from WebMD.com and many other websites and blogs). However, contrary to these publishers, Iconocast adds value to the content presented. The new Iconocast technology provides the most accurate updates on important and valuable health and science news inside a (green-border) table (Google News). Are past news or articles worth searching? Yes, we believe past articles are still valuable if they are effectively updated. Majority of these articles are truly timeless.
How does it work for today's article? Before showcasing today's article, the new Iconocast algorithm also presents links to substantially more views, articles, and news inside a Green Border Table in regards to the article on the page. In most cases the first or second links provided by Google News inside the table is to the original source of the article. Most people click on those links and land on the page where the original article is located. Website that participate in Google news and their articles show up in Iconocast have experienced an increase in traffic (also from the back-links or the link popularity that Iconocast provides). If you are not participating in Google news, Google will be happy to consider your site. We also strongly believe the more views and news about the same article, the more information, intelligence, and much more trustworthy is that article. This is an effective way for the reader to expand on the information and make sure that the article has validity and is reliable. Let us examine some examples. Take a look at this article: The Associated Press : Ad gives hot dogs a bum rap, experts say. If you examine both Google News and Google Scholar results, you get much more important news on what really causes colon cancer, what might help, what prevents, and what is more risky than the poor Hot Dogs. Of course we can never compete with a company as larger as the The Associated Press, however, we strongly believe we have justifiably added value over what they are presenting. Here is another example : CIA, FBI push 'Facebook for spies' If you examine the Google News Table, you get an expanded view of the activities (private social networking system for the CIA, the FBI and the National Security Agency called A-Space), and Google Scholar will give you important legal issues, privacy issues, and other important intellectual views.

Here is another example: Sarah Jessica Parker Removes Trademark Mole. Notice there are more than 100 articles that validate the news about the mole disappearance. After seeing the links to all these 100 article, don't you feel a bit more confident that the mole is really gone? Or check out this one : Miley Cyrus Without Clothes On in the Shower ; is this true? Fake? If you examine the information and news inside the Green Border Table on the page, you will quickly realize they are fake. These two examples and many, many other examples we can bring justify a system of check and balances to examine the validity of what people actually put out on the Internet. One can confidently say that Iconocast is based on our correct system of "Check (- the article) and Balances (- Google News)". No other News Agency provides the same service as Iconocast does. Everyday, Iconocast is viewed, searched and utilized by FBI, CIA, US Military (more than 54,000 hits so far for September), US Government (more than 29000 hits for September; see the table below), NSA, almost all private background checking agencies, NBC News, Apple Computer, Government News Agencies, Department of Health, CDC, and many other health related websites.

September: US Government & US Military Usage of Iconocast.com
Hits Files KBytes Organization
65094
29448
8181940
US Government
65189
28686
3770872
US Military

What is the significance of our system? To do a quick search in Google News on the relevant keywords of the article, we are able to identify what each article is about by just examining the title of the article. How reliable is our system? Look at this example : How much risk can you handle? Making better investment decisions. The system correctly identifies the keywords: "you + risk + investment" right at the top of the Green Border Table. This is not an easy task. There are just too many other words in that title such as: How + much + can + handle + Making + better + decision. All these words were correctly eliminated. We strongly believe we have achieved something substantial here.
In addition, Iconocast is the very first International Multimedia News Library, providing updated archived news translated to more than 7 languages.

world coverage

It is now well known that satellite dish (tv) and the start of the Internet were very instrumental in break up of the tyrannical regime of Soviet Union. I say why stop there? Why not translate our good values (healthy living, healthy eating, quality arts, book reviews, green living, ..... ) in the western free society for everyone in the world? Compared to racy television programs that are translated today (e.g. Bachelorette, Lipstick Jungle), isn't this a better representation of the western values? Iconocast main focus are health, science, technology, and arts. In some cases we have also collected business, real estate, books review, entertainment, gossip, and movie review.
Iconocast acts only as a library for these collections. What does it mean by library? It means we do not present these articles on daily basis (contrary to the news we receive from Universities and research institutes; there is no gossip news on today.htm page). We only save them for future reference and of course these articles can always be searched inside Iconocast by using the Google Search below on this page. In reality we recycle the past content (gossips and entertainment news) with today Google News. We do not intend to violate any copyright laws. If we have missed a link to the original article, we will correct this error. Iconocast is the very first Internet Library that is capable of recycling (value added) the past content. Just not too long ago there was a news (gossip) regarding the iPod effect on Heart Pacemaker. Two weeks later it was known that iPod has absolutely no effect on Pacemaker. Iconocast is the only Internet Library that corrected this content (gossip and rumors) by providing recent Google News at the top of the mentioned article which refuted the iPod harm on pacemaker. I wish someone could have calculated the loss to Apple computer for that period of doubt and more important the loss to the society for temporarily losing its trust on one of the best gadgets ever invented. Take a look at this one: Leaked Document Shows Verizon's Psyops Anti-iPhone Propagands. Now if you examine the Google News Table, you get a better, fair and expanded view on iPhone and all the neat things it can do. Isn't this more fair? You also get competitive analysis, and news on future Google Cell Phone Android. This is what we call check, expand, fair, and balance. Because there are so many wild and unchecked information on the Internet, some people joke that WWW stand for Wild Wild Web. We just like to hopefully remove the sarcasms.

I personally love the music of Amy Winehouse. It is a shame how much garbage is written on the Internet about Amy (e.g.:Amy Winehouse's hair extentions harvested from corpse). It is just as if we love to destroy and tear apart personalities and characters if they are famous or talented. We should wait another 100 years until someone with her talents give us enjoyment.
We strongly believe there is a justified opportunity for correcting gossips and false accusations, and it is to the advantage of the society for a healthy rule of mass communication and intelligence. Iconocast can also be used as an instrument that can remove burden of the liability of the shoulders of those who distribute false news and gossips unknowingly. How important is this effort? Recent article such as "Lawsuits Against Bloggers Seen Rising; Since 2004, 159 Court Actions Have Targeted Citizen Journalists for Libel and Other Charges" is a good indication.
In summary, there is really no difference between Iconocast and your city library with one unique advantage that Iconocast adds value by recycling the news with today's content.

And finally, I like to dedicate this website to the loving memory and honor of Tim Russert and his inspiring legacy. Just like us, he loved the News. He used to say if it's Sunday, it's meet the press. We like to say, if it's in the Internet, it is either expanded, updated, validated or refuted in Iconocast, not just in English, but in Spanish, Portuguese, German, Japanese, Italian, ......


Creative People

Here are the steps to creativity and secrets of creative people. No one has ever got off the bed and was a Picasso. No one!

My suggestions to those who like to be creative is to find something, a task, hobby, or profession that you find purified, noble and virtuous. Then copy your favorite leader, teacher, master or mentor. We all have to start with copying before we are creative in our fields. Even the most successful surfer, surgeon, rock climber had to copy his/her first teacher. At first, Picasso also copied. It does not matter how long you have to imitate, copy, plagiarize (give the credit of course), duplicate, or replicate. It does not matter. Don't forget you have to find what you do purified, noble and virtuous. If you don't, it will not work for you. It never works. What about those who have been copied? The smart and open minded have a saying: "Imitation is the highest form of flattery". The closed minded who were lucky once, complain.....This closed mindedness impedes creativity in our great country. Should you be happy that you copy? No! Absolutely not, and through this unhappiness that is the motivation you gain to become creative.

OK, you might think we are a bit unorthodox here and claim things (copying and plagiarizing) that might make people roll their eyes. So we like to bring some great and unique examples. We truly believe copying and plagiarizing will only help those who are true to their tasks and truly find what they do noble and virtuous. We strongly believe these are the people who will eventually become creative and will lead greatly. Do we have an example? Yes we do. Boston University, where Dr. King got his Ph.D. in systematic theology, conducted an investigation and found that he plagiarized major portions of his doctoral thesis. We do not mention this to diminish Dr. King's accomplishments. Totally contrary. We only mention this to foster our own argument. We strongly believe the creativity will eventually come to people once they gathered more insights. And, so did Dr. King. How do you think Japanese did it? How did they become so creative? They copied in 50s and 60s. When they were able to accumulate enough insights into building Cars, TVs,....they stormed out with creativity and ingenuity. Ronald Reagan enjoyed quoting Thomas Paine ("We have it in our power to begin the world over again."! ). Kelsey Grammer was imitating Bob Hope in Frasier and his Dad was John Wayne. Now imagine putting these two characters in one show. What do you get? Cheers! Where was the creativity? The creative part was the fact that you did not notice it. It was done with so much skill and creativity that it was not noticeable.

I like to make sure I am clear on the fact that it is the task that must be found noble and virtuous and not copying or plagiarizing. Copying is never noble, however, if you find the task noble, we believe copying will help and will lead toward creativity. Barak Obama also quotes Thomas Paine when he says I am Citizen Of The World! Did anyone notice? Of course they do. But since they have so much respect for Barak or even they, themselves, copy (I mean the so called elite themselves) they shot their mouth. Does Barak ever says Thomas Paine said it first in sometimes around 1774 (giving credit)? No! I like to challenge Barak to come up with some new and creative stuff and so did John F. Kennedy (And so, my fellow Americans, ask not what your country can do for you; ask what you can do for your country. My fellow citizens of the world, ask not what America will do for you, but what, together, we can do for the freedom of man.). Here what I suggest to Barak. Motivate people to become creative again. Ask them not to leave their job for day trading. Challenge people to study science and engineering again. Challenge parents to appreciate creativity in their children.

The moral of the story? Everyone copies. Only those who truly find the task, the occupation, the career noble and virtuous and will concentrate to perfect it and develop insights, will be creative. Why did entrepreneurship and creativity flourished in Ronald Reagan Era? Because Ronald Reagan was himself creative and a political entrepreneur ("I will not make age an issue...I am not going to exploit my opponent's youth and inexperience" ). Lucky are those who find serving their community and this great country noble and virtuous.

In the process of copying, you will concentrate on the task. Then you develop insights about the task. The trick is to combine finding nobility, concentration and developing insights in a spiral circle. Each will strengthen the other in a spiral manner on a circle. In other words, the more you find the task purified, noble and virtuous, the more you will concentrate and the more you will develop insights. The more you concentrate, the more you will find it virtuous and the more you will develop insights. The more you develop insights, the more you will concentrate and the more you will find it virtuous. Each must help the other grow and become stronger and stronger. This is essential in the process. We call this the tornado process. Nobility, concentration and insights are the winds of the tornado and each wind pushes the other to make the tornado stronger and stronger. If the tornado process does not happen, the creativity is not there.

Inside the tornado process you need to develop good observation techniques. You will develop more intuition about the task and how to do it even better than your mentor or master. This will be the turning point from just copying to becoming creative.

Hopefully, it will come the day that you will realize you can be creative. It will just come to you. Believe me it will. One day you will find yourself in a Picasso kind position. It might take 5 years or 5 weeks or 5 days. It all depends how much natural talents you have, how powerful is your tornado, and how much you love what you do. We can not say for certain what talent is. Is it a byproduct of the tornado effect? We don't know. We believe it is. We like to believe we are all talented. We are. We just need to discover our own tornado process. Each one of us has a tornado process hidden somewhere. You need to find your own tornado process.

 

What are the sign of the tornado process?

If you find yourself doing something nonstop with an amazing energy you never thought you possessed, you are experiencing the tornado. Say, you can not stop playing the piano. You can not stop climbing that rock. You can not stop writing that novel.

These are all the signs of the tornado. Some jobs you do for 5 minutes and you want to die. Say, cleaning your kitchen. Believe me you are not born to clean kitchens or mowing the lawn. And that is good news.

 

An interesting question would be: How can I find what I am good at? What is my tornado?

I was not introduced to Argentine Tango music and dance until I was 38 years old. Then I discovered some sort of tornado process when I started learning and copying my Argentine dance masters. You need to look for original signs and clues. When I was 25 or even younger I saw an Argentine Tango dance show conducted by Leslie Caron (she was in Father Goose with Cary Grant). I truly found it purified, noble and virtuous. Did I take the second step and the third step (concentration and developing insights into this dance) at 25? No! Unfortunately not. Sad!

Was I too old at age 38? Maybe. The moral of the story is this: If you find something immediately virtuous and noble, do not let go. Here is your clue. If you watch a surfer surfing and you find it immediately noble, do not give up. Go learn surfing. If you find a rock climber, climbing and you find it virtuous, do not just pass by. Go learn rock climbing. If you watch a piano concert and you think you have been mesmerized, do not just say it was just a show. Go learn piano.

Some 15 or 20 years ago, there was a TV show called LA Law. Then, I read in Wall Street Journal, that the application to Law Schools had tripled because of LA Law TV show. This might sound funny to you. But, this is the real tornado process in action for some of the young talented lawyers. There are so may Doctor shows on TV. From Gray Anatomy to ER and Hopkins. They are the best examples of developing tornado process for very young future doctors. So are shows like criminal justice or CSI.

 

Why are we talking about creativity on this page?

When I started our news publishing business I had no choice but to copy the big and successful Internet news publishers like seattletimes.com or Yahoo News. I had no journalism background. I worked nonstop for 5 years. Sometimes I put like 18 hours or more a day to run this website. Was I happy I could not contribute something new, creative? Of course I was not happy. But this is the price you pay until you get there and become creative. Hopefully there will be a point when you have gatherer enough insights and intuition. When I had enough intuition that I could be creative, I developed our Google news table at the top of every news we publish. I invented a very unique and effective algorithm to discover the keywords from the title of the news. Up to 5 months ago, every news was handled one by one. Now everything is an automatic process done by a software engineered by me. I only hope you find it useful and you also find it creative. One more thing; do I still work 18 hours or more. Sadly the answer is yes. The tornado will never go away. This is the amazing part of the process. Like it or not, once the tornado gets going, you can not stop the tornado. YOU CAN NOT!

Who invented the Tornado Process? The Tornado process (only named by me) is more than 5000 year old method used by Buddhist Monks to meditate. If you think about it, it really applies to anything we do and why we do. Imagine courting a woman. Every man find his woman purified, noble and virtuous. I have met few women who have told me they have never been in love. Tornado is the process of finding love. The first step in finding love is to find a woman or man that you find totally purified, noble and virtuous. You will define the nobility and the ways you believe someone is virtuous. Then you concentrate on that person and then you find insights about her/him. This is the part that every woman says I like him to notice the detail about me. That really mean that she/he wants him/her to develop insights about the opposite. When the tornado develops about a woman or man, love is created.

Who is currently the most famous Tornado man? Perhaps the most famous Tornado man is Michael Phelps. Michael does nothing but swim, eat and sleep. And he has been doing it for more than 8 years now. Last thing I heard was that swimming pools all over the country are filled with kids.

Today I heard they are not going to allow soft baseball in the next Olympics. Why? Because US is too good. This is again the sign of closed mindedness. Next they will ban Basketball and then Swimming,.....

If you like to know more about the tornado process, see www.motivationbook.com.

 


Looking at beautiful art can act as a painkiller

Beauty is truth, the English romantic poet John Keats once wrote, but according to the latest scientific research it is also a painkiller.

Looking at a beautiful piece of art has long been said to have the power to heal emotional wounds but the new research also claims it offers a distraction from physical pain.

 
Vincent Van Gogh's Starry Night, Sandro Botticelli's Birth of Venus and Fernando Botero
Works by Vincent Van Gogh, such as Starry Night [left] and Sandro Botticelli's Birth of Venus were deemed beautiful while paintings by Fernando Botero [inset] were viewed as ugly

The research carried out by the University of Bari in Italy could help vindicate hospitals who are accused of wasting money on art and decor as it suggests a pleasant environment helps patients overcome discomfort and pain.

A team headed by Professor Marina de Tommaso at the Neurophysiopathology Pain Unit asked a group of men and women to pick the 20 paintings they considered most ugly and most beautiful from a selection of 300 works by artists such as Leonardo da Vinci and Sandro Botticelli.

They were then asked to contemplate either the beautiful paintings, or the ugly painting, or a blank panel while the team zapped a short laser pulse at their hand, creating a sensation as if they had been pricked by a pin.

The subjects rated the pain as being a third less intense while they were viewing the beautiful paintings, compared with when contemplating the ugly paintings or the blank panel.

Electrodes measuring the brain's electrical activity also confirmed a reduced response to the pain when the subject looked at beautiful paintings.

While distractions, such as music, are known to reduce pain in hospital patients, Prof de Tommaso says this is the first result to show that beauty plays a part.

The findings, reported in New Scientist, also go a long way to show that beautiful surroundings could aid the healing process.

"Hospitals have been designed to be functional, but we think that their aesthetic aspects should be taken into account too," said the neurologist who published her findings in the paper Aesthetic Value of Paintings (And) Affects on Pain Thresholds.

"Beauty obviously offers a distraction that ugly paintings do not. But at least there is no suggestion that ugly surroundings make the pain worse.

"I think these results show that more research is needed into the how a beautiful environment can alleviate suffering."

The 12 volunteers, six female and six male, were picked randomly from the student body at the university and were aged between 22 and 38. They were asked to choose their favourite paintings from the website http://wwar.com/artists/.

Pictures they liked included Starry Night by Vincent Van Gogh and Botticellis Birth of Venus. Pictures they found ugly included works by Pablo Picasso, the Italian 20th century artist Anonio Bueno and Columbian Fernando Botero.

One of the problems with the study for those wishing to reduce pain is the subjective nature of beauty.

Edvard Munch's The Scream was deemed by some people as beautiful.

"These people were not art experts so some of the pictures they found ugly would be considered masterpieces by the art world," said Prof de Tommaso.

 

Today's Health, Science, Technology, Personal Finance News

(please report bugs and errors: suzanne@liveinfospace.com)

 

Six dos and dont's of heartburn relief

If you're prone to heartburn, or even if you've got a tough stomach—here are some tips to help stave off tummy troubles.

  • Don’t eat spicy, acidic, or fatty foods or drink too much alcohol or lots of caffeinated or carbonated drinks. Limit chocolate, garlic, onions, and peppermint.
  • Do sleep on your left side to avoid putting extra pressure on the stomach. Also, keep your head elevated 4 to 6 inches if you suffer from nighttime acid reflux.
  • Don’t snack right before bedtime. Stop eating and drinking 3 hours before you lie down.
  • Do try to get more fiber in your diet. In addition to improving your overall health, there is some evidence that getting more fiber may reduce heartburn symptoms.
  • Don’t smoke. Nicotine relaxes the esophageal sphincter and increases acid production.
  • Do watch your weight. Being even slightly overweight puts pressure on the lower esophageal sphincter, causing reflux. Losing just a few pounds can help.

Read more on how to sooth your stomach (free), find out if you're at risk for gastroesophageal reflux disease (GERD) (free), and check out our Treatment Ratings for heartburn and GERD (subscribers only).


Tip of the day: Healthy eating for frequent flying

Frequent travel often means eating lots of airport food--typically fries, burgers, and a hodgepodge of salty and sugary snacks. Instead of binging at the fast-food joints in airport terminals, pack healthy snacks, such as baked tortilla chips, unsalted nuts and pretzels, dried fruit, or low-fat cheese sticks to hold you over during a flight.

Read more on travel health and on how to NOT get sick while flying.

 

     

Deactivating a cancer growth promoter

Three enzymes called phosphatases that shut down a molecule called SRC-3 (steroid receptor coactivator 3) could provide a new pathway for fighting cancer, particularly tumors of the breast and prostate, said researchers at Baylor College of Medicine in a report that appears in the current issue of the journal Molecular Cell.

"This kind of information provides a target for the production of drugs against cancer," said Dr. Bert O'Malley, chair of molecular and cellular biology at BCM. "One can already find drugs that stimulate or inhibit phosphatases in other disease processes."

O'Malley and his colleagues had already determined that SRC-3 is an oncogene or cancer-promoting gene as well as a master switch in the cell. Phosphorylation or adding a phosphate molecule activates its cancer-promoting activities. In this study, the researchers identified three phosphatases that promote removal of the phosphate and thus halt the activity of SRC-3.

Of the three identified, PDXP, PP1, and PP2A, PP1 not only stops SRC-3 activity, it also stops the degradation of the co-activator. SRC-3 then builds up in cells, but without the phosphate, it is a dead molecule that does not function and may even further inhibit tumor growth.

Providing new avenues for fighting cancer is an important outcome of basic science, said O'Malley, who is also associate director for basic research in The Dan L. Duncan Cancer Center at BCM. "In cancer right now, many drugs work the same way. They are toxic to all cells. Because the cancer cell grows faster, the drug is more toxic, but there is nothing selective about the process. In the past decade, we have realized that there has to be a better, more intellectual approach to cancer. In fact, some already exist."

For example, the drug Herceptin targets breast cancer cells that carry the protein Her2/neu. Finding drugs that stop the activation of SRC-3, found at high levels in some breast tumors, could provide another avenue of treatment that could target just the cancer cells.

One study, published by Dr. C. Kent Osborne, director of the Lester and Sue Smith Breast Center at BCM, showed that women whose tumors have both the Her2/neu protein and high levels of SRC-3 are less likely to be helped by drugs such as tamoxifen and more likely to die quickly of their disease. Finding a way to stop Her2/neu and shut down SRC-3 could make the tumor cell's growth controllable, O'Malley said.

 

###

Others who took part in this work include Chao Li, Yao-Yun Liang, Xin-Hua Feng, Sophia Y. Tsia and Ming-Jer Tsai, all of BCM.

Funding for this study came from the National Institutes of Health and the Welch Foundation.

After the embargo lifts, this report can be found at www.molecule.org.

For more information on basic research at Baylor College of Medicine, please go to www.bcm.edu/fromthelab.


Simple device which uses electrical field could boost gas efficiency

With the high cost of gasoline and diesel fuel impacting costs for automobiles, trucks, buses and the overall economy, a Temple University physics professor has developed a simple device which could dramatically improve fuel efficiency as much as 20 percent.

According to Rongjia Tao, Chair of Temple's Physics Department, the small device consists of an electrically charged tube that can be attached to the fuel line of a car's engine near the fuel injector. With the use of a power supply from the vehicle's battery, the device creates an electric field that thins fuel, or reduces its viscosity, so that smaller droplets are injected into the engine. That leads to more efficient and cleaner combustion than a standard fuel injector, he says.

Six months of road testing in a diesel-powered Mercedes-Benz automobile showed that the device increased highway fuel from 32 miles per gallon to 38 mpg, a 20 percent boost, and a 12-15 percent gain in city driving.

The results of the laboratory and road tests verifying that this simple device can boost gas mileage was published in Energy & Fuels, a bi-monthly journal published by the American Chemical Society.

"We expect the device will have wide applications on all types of internal combustion engines, present ones and future ones," Tao wrote in the published study, "Electrorheology Leads to Efficient Combustion."

Further improvements in the device could lead to even better mileage, he suggests, and cited engines powered by gasoline, biodiesel, and kerosene as having potential use of the device.

Temple has applied for a patent on this technology, which has been licensed to California-based Save The World Air, Inc., an environmentally conscientious enterprise focused on the design, development, and commercialization of revolutionary technologies targeted at reducing emissions from internal combustion engines.

According to Joe Dell, Vice President of Marketing for STWA, the company is currently working with a trucking company near Reading, Pa., to test the device on diesel-powered trucks, where he estimates it could increase fuel efficiency as much as 6-12 percent.

Dell predicts this type of increased fuel efficiency could save tens of billions of dollars in the trucking industry and have a major impact on the economy through the lowering of costs to deliver goods and services.

"Temple University is very excited about the translation of this new important technology from the research laboratory to the marketplace," said Larry F. Lemanski, Senior Vice President for Research and Strategic Initiatives at Temple. "This discovery promises to significantly improve fuel efficiency in all types of internal combustion engine powered vehicles and at the same time will have far-reaching effects in reducing pollution of our environment."

 

###

NOTE: Copies of this study are available to working journalists and may be obtained by contacting Preston M. Moretz in Temple University's Office of News Communications, 215/204-4380 or pmoretz@temple.edu.

A prototype of the original device is available for photos in Dr. Tao's lab at Temple, while the current device being tested on the diesel trucks can be viewed by contacting STWA.

SOURCE CONTACTS:
Rongjia Tao, Temple University, 215/204-7651 or rtao@temple.edu
Joe Dell, SWTA, 610/781-0795 or joedell@live.com


Antidepressants may damage male fertility

Last Updated: 2008-09-24 15:19:18 -0400 (Reuters Health)

LONDON (Reuters) - Common antidepressant drugs may reduce some men's fertility by damaging the DNA in their sperm, according to scientists.

A study of 35 healthy men given paroxetine - sold as Paxil or Seroxat by GlaxoSmithKline - found that, on average, the proportion of sperm cells with fragmented DNA rose from 13.8 percent before treatment to 30.3 percent after just four weeks.

Similar levels of sperm DNA damage have been linked to problems with embryo viability in couples trying to have children. The research by Peter Schlegel and Cigdem Tanrikut of the Cornell Medical Center in New York was reported in New Scientist magazine and is due to be presented in November at a meeting of the American Society for Reproductive Medicine.

A copy of the study abstract was made available to Reuters.

"The fertility potential of a substantial proportion of men on paroxetine may be adversely affected by these changes in sperm DNA integrity," the experts concluded.

The study adds to concerns voiced by the same doctors in 2006, after finding that two men had developed low counts of healthy sperm following treatment with two different selective serotonin-reuptake inhibitors (SSRIs).

SSRIs like Paxil/Seroxat and Eli Lilly's Prozac, both of which are now available generically, are the most commonly prescribed class of antidepressant.

Glaxo said it was reviewing the investigators' findings, since the study was not conducted by the company.

"These medicines remain an important option, in addition to counselling and lifestyle changes, for treatment of depression and this study should not be used to cause unnecessary concern for patients," a spokeswoman said.

"Patients should discuss their situation with their doctor before stopping use of their medicine."

Allan Pacey, Senior Lecturer in Andrology at the University of Sheffield, said the apparent increase in sperm DNA damage was "alarming", although he noted the level at which damage becomes clinically significant was open to debate.

"It is a shame that the authors appear not to have conducted a randomised controlled trial which would be the most scientific way to investigate the drugs effects, but I agree that the results are of concern and need to be investigated further," he said.

SSRIs have long been known to depress libido in some men and previous research has also found that women taking the medicines are more likely to have a low birth weight baby.

Copyright © 2008 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.


Fish in children's diet cuts eczema risk: study

Last Updated: 2008-09-25 9:00:54 -0400 (Reuters Health)

(Embargoed for release at 2301 GMT Sept 24)

LONDON (Reuters Life!) - Feeding babies as little as one portion of fish before they are nine months old may cut their risk of developing eczema, Swedish researchers said on Thursday.

Introducing fish of any type into the diet curbed the risk of contracting the skin condition by 25 percent compared with children who never ate it, Bernt Alm, a pediatrician at the University of Gothenburg in Sweden, and colleagues reported in the British Medical Journal.

"The main finding was that early introduction of fish was beneficial," Alm said in a telephone interview. "There was no link with the amount of fish or type of fish. We think it is more the timing of the introduction."

Eczema is a chronic condition affecting between 10 and 15 percent of children that can cause the skin to become itchy, red, dry and cracked. It often affects those prone to allergies.

The Swedish study is part of research tracking the long-term health of nearly 17,000 babies.

The researchers found that genes played an important role in the development of eczema but breast-feeding and keeping a furry pet in the house had no effect.

Fish in the diet appeared to be important, but Alm said it would take further investigation to establish why. There was no extra protection from fish rich in omega-3 fatty acids, which provided other health benefits, Alm said.

"It must have something to do with its influence on the developing immune system," he added.

Copyright © 2008 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.


Living near asbestos plant raises cancer risk

Last Updated: 2008-09-25 13:01:11 -0400 (Reuters Health)

NEW YORK (Reuters Health) - People who have ever lived a short distance from an asbestos-manufacturing plant may have an elevated risk of a rare form of cancer, a new study suggests.

Asbestos is a heat-resistant fibrous material that was once widely used in insulation, fireproofing, tiles and a host of other building materials. Breathing in airborne asbestos fibers can contribute to lung cancer, as well as mesothelioma -- a rare cancer of the membrane surrounding internal organs. It most often affects the tissue that lines the chest cavity and protects the lungs.

People who have ever had on-the-job exposure to asbestos -- in industries like construction and insulation manufacturing -- are at greatest risk of mesothelioma.

The new findings now suggest that people who've ever lived near an asbestos manufacturing plant are also at risk of developing the disease, several decades later.

In the study, Japanese researchers found higher-than-expected death rates from mesothelioma among people who'd lived near a now-closed asbestos cement pipe plant between 1957 and 1975.

The risk steadily declined as residents' distance from the plant increased, with elevated mesothelioma rates seen among people living up to roughly 1.5 miles downwind of the plant.

Residents who died of mesothelioma developed symptoms of the disease an average of 43 years after their first year living near the plant, according to Drs. Norio Kurumatani and Shinji Kumagal. The findings are published in the American Journal of Respiratory and Critical Care Medicine.

The researchers based their findings on 35 men and 38 women who had lived near the asbestos pipe plant between 1957 and 1975 and died of mesothelioma sometime between 1995 and 2006. None had had any occupational exposure to asbestos.

The mesothelioma death rate for these residents was four times what would be expected. And the greatest risk was seen among men and women living within 300 meters of the plant; the death rate among women was 41 times the expected rate, while the rate among men was 14 times the expected figure.

The findings strongly support exposure to the asbestos plant as the cause of these mesothelioma cases, according to Kurumatani and Kumagal.

In 2006, the researchers note, the Kubota Corporation, which ran the plant before it closed, established a compensation fund for people who developed asbestos-related diseases after having lived within kilometer -- or 1.6 miles -- of the site during the time it used asbestos.

Kurumatani is at the Nara Medical University School of Medicine in Kashihara, and Kumagal is affiliated with the Osaka Prefecture Institute of Public Health in Osaka.

SOURCE: American Journal of Respiratory and Critical Care Medicine, September 15, 2008.

Copyright © 2008 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.


Variety Of Foods The Key For Child Nutrition

New research shows that most children have a diet that contains enough essential vitamins and minerals.

Analysis of the Government's own survey of children's diets and nutritional status has shown that the average child gets the recommended level of most vitamins and minerals, even though they consume more added sugars than recommended.

The study published online in the British Journal of Nutrition, looked at a nationally representative sample of children aged 4-18 years who took part in the National Diet and Nutrition Survey. It found that the average child consumed levels of vitamins and most minerals that met recommendations, and in many cases, comfortably exceeded them. These conclusions were based on records from 7-day weighed food diaries and were confirmed by biochemical measurements of blood samples.

'The children in this study were healthy British children' said Mrs. Sigrid Gibson, lead author on the study. 'Some children who are fussy eaters might get lesser amounts of nutrients from their limited range of food choices, and if they also eat a lot of added sugars they might be at risk'. But she added, 'the solution is to broaden their choice of foods it does not appear that simply discouraging sugar consumption would have any real benefit'.

Mrs. Gibson is an independent nutrition consultant, with over 20 year's experience of working with the government, food industry and agencies such as the Food Standards Agency. She is the author of over 30 peer-reviewed scientific publications and is a regular contributor to nutrition journals. 'There is an over-emphasis on avoiding sugar at all costs rather than having a balanced diet' said Mrs. Gibson. 'Concerns that added sugars 'dilute' the diet and jeopardise essential nutrients are just not founded'.

The school food trust works to improve the quality of school lunches by providing information on the Government's food and nutrient standards. They recommend 10% of your energy intake should come from added sugars. The children in this study had on average 15% of their energy from added sugars and still had enough of most vitamins and minerals.

THE SUGAR BUREAU
The Sugar Bureau
Duncan House, Dolphin Square
http://www.sugar-bureau.co.uk

New Study Finds Dangerous Carcinogen In Fast-Food Grilled Chicken

A new study published in Nutrition and Cancer shows that consumers are exposed to a known carcinogen when they consume grilled chicken. One hundred samples from seven popular chain restaurants were analyzed by an independent laboratory, and PhIP, a known human carcinogen, was found in every sample.

PhIP forms when meat, especially chicken, is grilled or pan-fried at high temperatures, and, for more than a decade, it has been on the California governor's list of chemicals known to cause cancer. The carcinogen-containing grilled chicken samples, including salads, sandwiches, and entrées, were collected from McDonald's, Chick-fil-A, Chili's, TGI Friday's, Outback Steakhouse, Burger King, and Applebee's.

"Grilled chicken is the largest source of PhIP, a potent carcinogen," says Kristie Sullivan, M.P.H., lead author of the new study and a toxicologist with the Physicians Committee for Responsible Medicine. "We found this carcinogen in every single sample of grilled chicken taken from restaurants in every part of California."

PhIP is one of a group of carcinogenic compounds called heterocyclic amines (HCAs), and it is a known mutagen that can cause DNA damage that can lead to cancer. In human studies investigating well-done meat consumption and cancer risk, the highest risk is for cancers of the prostate, colon/rectum, and breast. In 2005, the federal government officially added HCAs to its list of anticipated human carcinogens. Even small amounts can increase a person's risk of developing cancer.

People consuming PhIP and similar compounds are more likely to develop cancer, compared to other people. The new study shows that PhIP is pervasive in grilled chicken products. "You don't want fried chicken, obviously, with all its fat and cholesterol, but it turns out that grilled chicken is peppered with chemicals clearly linked to cancer," Ms. Sullivan said. Chemist Michael Erikson, M. S., toxicologist Chad Sandusky, Ph.D., and Neal Barnard, M.D. are co-authors.

Founded in 1985, the Physicians Committee for Responsible Medicine (PCRM) is a nonprofit organization that promotes preventive medicine, conducts clinical research, and encourages higher standards for ethics and effectiveness in research.

Physicians Committee for Responsible Medicine (PCRM)

The Effect On Muscle Repair And Regeneration Of Cholesterol-Lowering Drugs

Statins are powerful drugs that reduce "bad" cholesterol and thus cut the risk of a heart attack. While these medications offer tremendous benefits to millions, they can carry side effects for some. The most frequently reported consequence is fatigue, and about nine percent of patients report statin-related pain. Both can be exacerbated when statin doses are increased, or physical activity is added. The results of a new study may offer another note of caution for high-dose statin patients. Working with primary human satellite cell cultures, researchers have found that statins at higher doses may affect the ability of the skeletal muscles - which allow the body to move - to repair and regenerate themselves.

The study is entitled "Simvastatin Reduces Human Primary Satellite Cell Proliferation in Culture." It was conducted by Anna Thalacker-Mercer, Melissa Baker, Chris Calderon and Marcas Bamman, University of Alabama at Birmingham. They will discuss their findings at the American Physiological Society (APS; http://www.The-APS.org) conference, The Integrative Biology of Exercise V. The meeting is being held September 24-27, 2008 in Hilton Head, SC.

The Study

Statins have been reported to have adverse effects on skeletal muscle in both human and animal models causing cramping and fatigue and potentially myopathy. Relatively little is known regarding the effect of statins on the muscle progenitor cells (i.e., satellite cells (SC)) which play a key role in skeletal muscle repair and regeneration following exercise or injury. SC remain in a quiescent state until stimulated to proliferate. Statins are known to have antiproliferative effects in other cell types and therefore may inhibit or effect this critical step in muscle repair. Thus it is important to understand the influence of statins on SC function which may further affect the overall health and physiology of human skeletal muscle..

The study examined the proliferative capacity of human satellite cells in culture, which were exposed, to a lipophilic statin: simvastatin. The aim of the study was to determine SC viability during proliferation when treated with statins which may be indicative of the ability of SCs to undergo mitosis (i.e. divide to make new cells).

The research team used primary cell lines isolated from quadriceps muscle biopsies. SC were mixed and grown for 48 hours with several concentrations of statin: 0.0, 0 plus the solvent DMSO (control), 0.05, 0.1, 1.0, 10, or 100µM. The MTS assay was utilized to measure cell viability/reproducibility.

Additionally the investigators determined the effects of varying concentrations of simvastatin on SCs in different states (i.e., undergoing differentiation or differentiated into myotubes).

Key Findings

The researchers found the following:
  • There was a dose dependent decrease in the viability of the satellite cells at 1.0, 10 and 100µM concentrations of simvastatin. At approximately 5.0 µM concentration the viability of the proliferating cells was reduced by 50% (equivalent to the availability of simvastatin in circulation from a 40 milligram dose per day used in some patients). Specifically, the higher end concentrations led to reduced SC proliferation, which would likely negatively affect the muscle's ability to heal and/or repair itself.

  • There was no change in the viability of satellite cells at concentrations of 0.05 or 0.1µM.

  • Cell viability was reduced by approximately half in differentiating cells and myotubes with concentrations of 1.0 and 5.0 µM, respectively.
Next Steps

According to Dr. Thalacker-Mercer, a member of the research team, "While these are preliminary data and more research is necessary, the results indicate serious adverse effects of statins that may alter the ability of skeletal muscle to repair and regenerate due to the anti-proliferative effects of statins."

Looking ahead, she added, "We are very interested in these effects in the older population. It is possible that older adults may not be able to distinguish between muscle pain related to a statin effect or an effect of aging and therefore adverse effects of statins in older adults may be under-reported. Therefore, our next step is to examine statins among older adults."

Physiology is the study of how molecules, cells, tissues and organs function to create health or disease. The American Physiological Society (APS; www.The-APS.org/press) has been an integral part of this discovery process since it was established in 1887.

The APS Conference, The Integrative Biology of Exercise V, is being held September 24-27, 2008 in Hilton Head, SC.

Source: Donna Krupa
American Physiological Society

Wyeth's 'Superbug' Antibiotic, Tygacil (tigecycline), Commended For Innovation And Health Benefit

Wyeth's innovative antibiotic, Tygacil (tigecycline), developed to treat a range of superbugs, has been commended at the 2008 UK Prix Galien.

The Prix Galien is the pharmaceutical industry's premier award and is designed to recognise pharmaceutical innovation and the resulting health benefits it produces. The 2008 Prix Galien awards were made last night by Professor Sir Michael Rawlins, Chairman of the National Institute for Health and Clinical Excellence (NICE), who heads the Prix Galien judging panel.

Tygacil is the world's first glycylcycline intravenous antibiotic. It has an expanded broad-spectrum antibiotic activity and is the only such agent effective against resistant Gram-negative and Gram-positive organisms including the superbug MRSA- a national and global concern. As such, it offers a significant advance in the treatment of patients at risk of difficult-to-treat bacterial infections and gives doctors the confidence to successfully manage these conditions.

Antibiotic-resistant infections are a growing problem and a major concern both here in the UK and globally.1 In particular, healthcare associated infections (HAIs) or 'superbugs', including MRSA, cause significant morbidity and death among hospitalised patients, estimated by the National Audit Office as causing 5,000 deaths and contributing to 15,000 per year. 2 Furthermore there is rising public concern with the appearance of new resistant bacteria further complicating treatment.

The development and availability of Tygacil therefore represents an important new weapon in the armoury of antibiotics against resistant infections. Furthermore, early data suggest that Tygacil may have a low propensity to induce C difficile3, a rare but serious side effect of antibiotic use which places a significant burden on the NHS.

Dr Vignesh Rajah, Wyeth's Medical Director in the UK, said: "Wyeth is honoured to receive this commendation for Tygacil as it recognises the efforts - over 15 years - by our scientists and research staff to develop a much needed 'smart' antibiotic."

Dr Rajah continued: "The range of agents available to treat complicated, resistant infections - which are often caused by more than one type of bacterium - have become increasingly compromised in recent years due to the rapid emergence of multi-resistant bacteria. As a company, Wyeth is therefore especially proud to have developed Tygacil as the first glycylcycline antibiotic to help in the fight."

Welcoming the Prix Galien award for Tygacil, Professor Dilip Nathwani, Consultant Physician and Honorary Professor of Infection, Dundee, said: "In recent years, the development and introduction of new antibiotics for serious multi - resistant infections has been slow, so Tygacil offers us an important opportunity to clinically and cost-effectively manage some of these more difficult infections."

The Prix Galien

The Prix Galien recognises the pharmaceutical industry's outstanding achievement in the development of new medicines. An internationally recognised award, the Prix Galien was founded in France in 1969 by French pharmacist Roland Mehl and adopted by other countries including the UK. The Prix Galien is named after the ancient Roman philosopher and teacher Claudius Galenus (AD 131-201) who is generally recognised as the 'father of modern pharmacology'.

The problem of Healthcare Associated Infections (HAIs)

Here in the UK, HAIs are of mounting concern due to the escalation of multi-resistant pathogens or so called 'superbugs' such as MRSA. The National Audit Office estimates that 9% of UK in-patients suffer an HAI, equivalent to 100,000 cases per year causing 5,000 deaths and further contributing to 15,000 deaths per year.2 The UK has now one of the highest levels of meticillin-resistant Staphylococcus aureus (MRSA) in Europe.1 Furthermore there is rising public concern with the appearance of new resistant bacteria, further complicating treatment.

About Tygacil

Tygacil is licensed for use in the treatment of a variety of complicated intra-abdominal infections and complicated skin and soft tissue infections in adults.

Tygacil has been specifically engineered to overcome multiple bacterial resistance mechanisms. Its unique pharmacological profile and emerging clinical experience makes it a very important therapeutic option for clinicians to consider when treating serious infections in complicated patients at risk of resistant pathogens. Tygacil could replace existing agent and combinations and as such, reduce the development of multi-drug resistant pathogens in the hospital setting and collateral damage associated with reliance on existing antibiotic classes.

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, haemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health. http://www.wyeth.com

References

1. European Antimicrobial Resistance Surveillance System (http://www.rivm.nl/earss/database/) Accessed September 2008

2. NAO Report by the Comptroller and Auditor General - HC 230 Session 1999-2000: The Management and Control of Hospital AcquiredInfection in Acute NHS Trusts in England. Published 17th Feb 2000.

3. Evidence for low risk of Clostridium difficile infection associated with tigecycline. M.H.Wilcox Clin Microbiol Infect 2007;13:949-952

Wyeth Pharmaceuticals

Life-Extending Kidney Cancer Drug Commended For Health Benefit And Innovation

Torisel ® (temsirolimus), Wyeth's innovative new treatment for poor prognosis advanced renal cell (kidney) cancer, has been commended at the 2008 UK Prix Galien. The commendation was made in the Prix Galien's new 'orphan drug' category, introduced this year for the first time to recognise advances in treating rarer diseases.

The Prix Galien is the pharmaceutical industry's premier award designed to recognise pharmaceutical innovation and the resulting health benefits it produces. The 2008 Prix Galien awards were made last night by Professor Sir Michael Rawlins, Chairman of the National Institute for Health and Clinical Excellence (NICE), who heads the Prix Galien judging panel.

Torisel is used to treat a subset of patients with advanced renal cell cancer who have the bleakest outlook, often termed poor prognosis.

Wyeth's temsirolimus (Torisel), the product of many years' investment in terms of research and development, is the first treatment for poor prognosis advanced renal cell cancer to significantly extend patients' overall survival versus the standard existing therapy, interferon-alpha.1 In a clinical study, overall patient survival increased by almost half from 7.3 months to 10.9 months.1 There are approximately 450 patients in the UK with poor prognosis advanced renal cell cancer who would be eligible for treatment with Torisel.

"Wyeth is honoured to receive this commendation and in particular I would like to acknowledge all those involved in its development including the scientists, clinicians, patients and their carers, "said Dr Vignesh Rajah, Wyeth's Medical Director in the UK. "Torisel represents an important advance in treating patients diagnosed with poor prognosis advanced renal cell cancer. These patients have a bleak outlook so Torisel is vitally important to them in offering them the opportunity for increased life-expectancy and the chance to enjoy valuable time with loved ones."

Dr Rajah added: "Disappointingly, despite receiving this recognition at Prix Galien, Torisel may not be available to patients in the UK. NICE's recent draft guidance on the use of Torisel and other new kidney cancer drugs, if implemented, will mean these new treatments will not be recommended for use by the NHS."

"Nevertheless, I am hopeful that this commendation will add weight to the argument that it is unfair and inequitable to deny patients treatment with Torisel if appropriate, and that NICE should reconsider its draft guidance on the use of Torisel and these other drugs by the NHS."

About the Prix Galien

The Prix Galien recognises the pharmaceutical industry's outstanding achievement in the development of new medicines. An internationally recognised award, the Prix Galien was founded in France in 1969 by French pharmacist Roland Mehl and adopted by other countries including the UK. The Prix Galien is named after the ancient Roman philosopher and teacher Claudius Galenus (AD 131-201) who is generally recognised as the 'father of modern pharmacology'.

About TORISEL

TORISEL is the first and only renal cell cancer therapy proven to extend overall survival in the treatment of advanced RCC in patients with poor prognosis compared with interferon-alpha.1 An open-label, randomised, phase 3 study compared TORISEL alone, a combination of TORISEL plus interferon-alpha, and interferon-alpha alone as first-line therapy in 626 patients with advanced RCC who had at least three of six prognostic risk factors.1

In this study, TORISEL alone significantly increased median overall survival by 49 % compared with interferon-alpha alone (10.9 months for TORISEL vs. 7.3 months for interferon-alpha, P=0.0078).2 TORISEL was also associated with statistically significant improvement over interferon-alpha in the secondary end point of progression-free survival (PFS), when the disease does not get worse (3.8 months of PFS vs. 1.9 months of PFS, P<0.001).2

TORISEL was granted a marketing authorisation for the EU on 19th November 2007 by the European Commission. TORISEL is indicated for the first-line treatment of patients with advanced renal cell carcinoma who have at least three of six prognostic risk factors.3

Orphan medicines

Orphan drugs are medicines used to treat rare or so-called 'orphan' conditions. In the EU, these are categorised as conditions affecting less than 5 per 10,000 individuals.

A further category - 'ultra orphan' drugs - are medicines used to treat conditions with a prevalence of less than 1 in 50,0004. Torisel therefore fulfils the condition to be designated an 'ultra orphan' drug.

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, haemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

References

1. Hudes, G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-228
2. Data on file. Wyeth Pharmaceuticals CSR 64508
3. TORISEL UK SmPC Nov 2007.
4. NICE. Appraising Orphan Drugs 16 March 2006. Available here. Accessed September 2008.

Wyeth Pharmaceuticals

View drug information on Torisel

Natural Viagra? "Horny Goat Weed" Shows Promise In Lab Studies

Move over, Viagra! Researchers in Italy report that an ancient Chinese herbal remedy known as "horny goat weed" shows potential in lab studies as source for new future drugs to treat erectile dysfunction (ED). The study, which provides scientific evidence supporting the herb's well-known use as a natural aphrodisiac, is scheduled for the October 24 issue of ACS' Journal of Natural Products, a monthly publication.

In the new study, Mario Dell'Agli and colleagues point out that Viagra (sildenafil) and several other prescription drugs are now available for ED, or male impotence. ED affects an estimated 18 million men in the United States alone. Studies show, however, that these drugs may cause side effects such as headache, facial flushing, stomach upset, and visual disturbances.

To find better treatments, the scientists studied herbal extracts reputed to improve sexual performance. Scientists exposed the substances to an enzyme that controls blood flow to the penis and whose inhibition results in an erection. Of the extracts tested, "horny goat weed" was the most potent inhibitor of the enzyme. By chemical modification of icariin, the active ingredient purified from the extract, the scientists obtained a derivative with activity similar to Viagra and a potential for fewer side effects because it targeted the protein more precisely than sildenafil. - MTS

Article
"Potent Inhibition of Human Phosphodiesterase-5 by Icariin Derivatives"
Download Full Text Article

American Chemical Society

View drug information on Viagra.

Novel Mechanism To Reduce Nervous System Inflammation Identified By Researchers

Researchers at Georgetown University Medical Center have discovered a new way to limit inflammation caused by the activation of microglia - key immune cells in the brain. Although the role of such cells is to "clean up damage" after injury, they often worsen the damage by releasing toxic inflammatory factors.

In the October issue of the journal Glia, now published online, the scientists say that the type of chemical they used to deactivate these cells could possibly be developed as a drug to treat a variety of acute and chronic disorders marked by brain cell damage - including stroke, head and spinal cord injury, and possibly Alzheimer's disease and Parkinson's disease.

"Inflammation associated with the activation of microglial cells is an important factor that appears to contribute to tissue damage and disability in many of the important neurodegenerative disorders. By decreasing this inflammatory response, tissue loss after injury can be reduced. Thus, what we found in this study has important potential therapeutic implications for the treatment of a number of important neurological disorders," says the study's senior investigator, Alan I. Faden, M.D., a professor of neuroscience and director of the Laboratory for the Study of Central Nervous System Injury.

The research, led by investigator Kimberly Byrnes, Ph.D., an assistant professor in Faden's laboratory, centered on microglial cells, which react against pathogens that invade the brain, and also remove foreign material and damaged cells.

Byrnes describes microglial cells as just a little too good at their jobs. "They overdo it, perhaps because they don't have very good stop signals. They secrete a number of toxic chemicals designed to clear up infections and damaged tissue -- but in the process they can kill sensitive brain cells."

In this study, Byrnes, Faden and a team of four other researchers looked to see whether microglial cells express a certain receptor on their surface that Faden and his laboratory had previously found could be turned on in brain neurons to prevent cell death in response to injury. The receptor, the group I metabotropic glutamate receptor 5 (mGluR5), which also plays a critical role in modulating pain and addiction, was previously found in other types of brain cells.

The researchers found the receptor protein in microglia in cell culture. "That's a first," Byrnes says. They then showed that a selective activator of this receptor type, CHPG, could turn off microglial activity. This is the same chemical that Faden discovered could shut down certain kinds of suicide cell death (apoptosis) in neurons.

"We found that if we stimulate just this receptor, we can markedly reduce microglial release of key inflammatory factors and the ability of activated microglia to kill nerve cells," Byrnes says.

The receptor, therefore, appears to be a switch-off mechanism, a brake on the damaging effects of microglial activity. "This is possibly a way that the brain has designed to turn microglia off, but the problem is that these cells get many other signals that keep them turned on after injury."

Treating brain injury with a selective compound may be challenging, the researchers add. "Microglia also releases good chemicals, such as growth factors, to promote nerve cell regrowth and regeneration, so the trick will be to discretely use it after injury for a period of time."

But brain and spinal cord injury studies in animals, conducted after the present experiments were completed, have been very encouraging, Byrnes says. Those studies have not yet been published.

The study was funded by a grant from the National Institutes of Health. Coauthors include Bogdan Stoica, M.D., David Loane, Ph.D., and Angela Riccio, B.S., from Georgetown University Medical Center, and Margaret Davis, Ph.D., from the National Institute on Alcohol Abuse and Alcoholism.

About Georgetown University Medical Center

Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through our partnership with MedStar Health). Our mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing and Health Studies, both nationally ranked, the world-renowned Lombardi Comprehensive Cancer Center and the Biomedical Graduate Research Organization (BGRO), home to 60 percent of the university's sponsored research funding.

Source: Karen Mallet
Georgetown University Medical Center

Every Minute Matters During A Stroke

In an editorial response to a report in the September 25 issue of the New England Journal of Medicine on the efficacy of intravenous thrombolysis treatment in the hours after acute ischemic stroke, Patrick Lyden, M.D., professor of neurosciences and director of the UC San Diego Stroke Center, cautions that the study should not be interpreted to mean that such therapy can be withheld for hours or even minutes.

"The risk of withholding such treatment from patients with acute stroke greatly exceeds the risk of giving it," said Lyden. "The potential for reversing the disabling side effects of stroke declines with every passing minute."

The study, ("Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke") by Werner Hacke, M.D. et al, reports the findings from the European Cooperative Acute Stroke Study III (ECASS III).

The design of this study closely mirrored that of the original National Institute of Neurological Disorders and Stroke (NINDS) trial of recombinant tissue plasminogen activator (rt-PA) for acute stroke, a pivotal trial that Lyden helped lead that showed the first proven therapy for stroke. The important exception in the ECASS III trial is that the window of therapy was expanded to a period of three to four and a half hours, compared to under three hours in the NINDS trial.

According to Lyden, the very real peril of the BCASS III data is that some may take a slower approach to treating acute stroke.

"Nothing could be more wrong," Lyden states in the editorial. "As we look back on the past decade of thrombolytic therapy for stroke, it is very clear that our focus must remain on the door-to-needle time. Every minute matters during a stroke."

The UCSD Stroke Team is available 24 hours a day, seven days a week, at the UC San Diego Medical Center. Immediate diagnosis of a potential stroke can be made to determine the appropriateness of tPA therapy, approved in 1996 by the Food and Drug Administration for the treatment of ischemic stroke, which occurs in about 70 to 80 percent of strokes when a blood clot interrupts blood supply to the brain.

Lyden and colleagues at the UC San Diego Medical Center recently completed a first-of-its-kind study of its telemedicine program, which allows the stroke experts real-time visual and audio access to patients and their medical team at remote sites - linking the physicians across long distances to a patient's bedside via computer, using highly sophisticated video, audio and Internet technology to evaluate the patient. The "STRokE DOC" (Stroke Team Remote Evaluation using a Digital Observation Camera) system was proven to enable the consulting physicians to help the local medical team make appropriate treatment decisions, and better decisions than telephone consultations, when evaluating stroke patients across distant sites. The study was published online in Lancet Neurology on August 3, 2008. (View full press release and video at http://health.ucsd.edu/news/2008/8-4-telemedicine.htm.)

Lyden serves as a regular reviewer for journals such as Neurology, Stroke, and the Journal of Stroke and Cerebrovascular Diseases. Additionally, he serves as an ad hoc reviewer for Archives of Neurology and Experimental Neurology. He is a member of the editorial board of the Journal of Stroke and Cerebrovascular Diseases, a charter member of the editorial board of the International Journal of Stroke, and editor the book Thrombolytic Therapy for Acute Stroke.

Source: Debra Kain
University of California - San Diego


An Effective Strategy For Inhibition Of Cirrhosis

In China, the incidence of liver cirrhosis is still high, although new therapeutic approaches have recently been proposed, there is no established therapy for liver fibrosis, and Authors investigated the prevention effects of Chinese Medicine Qianggan-Rongxian Soup on liver fibrosis induced by DMN in rats. Chinese Medicin Qianggan-Rongxian decoction can inhibit hepatic fibrosis resulted from chronic liver injury, retard the development of cirrhosis, and notably ameliorate the liver function. It may be a safe and effective therapeutic drug for patients with fibrosis.

A research article published in the World Journal of Gastroenterology refers. The research team led by Chun-Hui Li from affiliated Hospital of Chengde Medicine College studied the inhibitory effect of Huangqi Zhechong decoction on liver fibrosis in rat.

Qianggan-Rongxian decoction, especially the medium-dose administration could decrease the area-density percentage of collagen fibrosis. HA, LN, and type IV collagen are good serum markers of hepatic fibrosis. In this study, the serum contents of these 3 markers in the model group were much higher than those of the controls. And the Qianggan-Rongxian decoction groups had significantly low HA, LN, and type IV collagen levels in serum than those in the controls, ALT and AST are indexes to describe liver functions. Most part of ALT is presented in the cytoplasm of liver cell, discharged in blood when degeneration, hyper permeability and necrosis of liver cells occur. So the increase of ALT level in serum reflects the degree of liver cell injury. Our study showed that the Qianggan-Rongxian decoction could decrease serum levels of ALT and AST in rats with hepatic injury caused by DMN. It indicates that Qianggan-Rongxian decoction may work through protecting the liver cells, which indicated that Qianggan-Rongxian decoction could successfully prevent hepatic fibrosis.

The mechanism of DMN-induced liver fibrosis has been shown to be associated with immune function, which is similar to the mechanism of human liver fibrosis. Thus, DMN-induced rat liver fibrosis may be a useful model for determination of liver fibrosis during drug screenin. The mechanism of the Qianggan-Rongxian decoction may need further research.

This study may provide a safe and effective strategy for inhibition of cirrhosis in clinical use.

Reference: Li CH, Pan LH, Yang ZW, Li CY, Xu WX. Experimental study of prevention effect of Qianggan-Rongxian decoction on fibrosis in rat livers. World J Gastroenterol 2008; 14(22): 3569-3573. http://www.wjgnet.com/1007-9327/14/3569.asp

Correspondence to: Chun-Hui Li, the department of pathology, affiliated Hospital of Chengde Medicine College, Chengde 067000, Hebei Province, China.

About World Journal of Gastroenterology

World Journal of Gastroenterology
(WJG), a leading international journal in gastroenterology and hepatology, has established a reputation for publishing first class research on esophageal cancer, gastric cancer, liver cancer, viral hepatitis, colorectal cancer, and H pylori infection. It provides a forum for both clinicians and scientists. WJG has been indexed and abstracted in Current Contents/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch) and Journal Citation Reports/Science Edition, Index Medicus, MEDLINE and PubMed, Chemical Abstracts, EMBASE/Excerpta Medica, Abstracts Journals, Nature Clinical Practice Gastroenterology and Hepatology, CAB Abstracts and Global Health. ISI JCR 2003-2000 IF: 3.318, 2.532, 1.445 and 0.993. WJG is a weekly journal published by WJG Press. The publication dates are the 7th, 14th, 21st, and 28th of every month. The WJG is supported by The National Natural Science Foundation of China, No. 30224801 and No. 30424812, and was founded with the title China National Journal of New Gastroenterology on October 1, 1995, and renamed WJG on January 25, 1998.

About The WJG Press

The WJG Press mainly publishes World Journal of Gastroenterology.

Source: Lai-Fu Li
World Journal of Gastroenterology

Factor Spurring Formation Of Inhibitory Synapses Gives Clues To Neurologic Disorders

Neuroscientists at Children's Hospital Boston have identified the first known "master switch" in brain cells to orchestrate the formation and maintenance of inhibitory synapses, essential for proper brain function. The factor, called Npas4, regulates more than 200 genes that act in various ways to calm down over-excited cells, restoring a balance that is thought to go askew in some neurologic disorders. The findings appear in the September 24 advance online edition of the journal Nature.

Synapses, the connections between brain cells, can be excitatory or inhibitory in nature. At birth, the rapidly developing brain teems with excitatory synapses, which tend to make nerve cells "fire" and stimulate their neighbors. But if the excitation isn't eventually balanced, it can lead to epilepsy, and diseases like autism and schizophrenia have been associated with an imbalance of excitation and inhibition. The creation of inhibitory connections is also necessary to launch critical periods -- windows of rapid learning during early childhood and adolescence, when the brain is very "plastic" and able to rewire itself.

Npas4 is a transcription factor, a switch that activates or represses other genes. The researchers, led by Michael Greenberg, PhD, director of the Neurobiology Program at Children's, demonstrated that the activity of as many as 270 genes changes when Npas4 activity is blocked in a cell, and that Npas4 activation is associated with an increased number of inhibitory synapses on the cell's surface.

The team further showed that Npas4 is activated by excitatory synaptic activity. "Excitation turns on a program that says, 'this cell is getting excited, we need to balance that with inhibition,'" explains Greenberg, who now also chairs the Department of Neurobiology at Harvard Medical School.

Finally, the researchers bred live mice that lacked Npas4, and found evidence of neurologic problems - the mice appeared anxious and hyperactive and were prone to seizures.

Greenberg and colleagues are now trying to learn more about the wide variety of genes that Npas4 regulates, each of which could give clues to synapse development and reveal new treatment possibilities for neurologic disorders. "If you have your hand on a transcription factor such as Npas4, new genome-wide technology allows you to essentially identify every target of the transcription factor," says Greenberg. One such target is neurotrophic factor (BDNF), which Greenberg and colleagues previously showed to regulate the maturation and function of inhibitory synapses.

Children's researchers Takao Hensch, PhD, and Michela Fagiolini, PhD, also in the Neurobiology program, plan to study the Npas4-lacking mice to see if they have abnormalities in the initiation of critical periods; colleague Chinfei Chen, MD, PhD, will also study the mice, further probing how their synapses develop.

The study was supported by the F.M. Kirby Foundation, the Nancy Lurie Marks Family Foundation, the Lefler Foundation and the National Institutes of Health. Yingxi Lin, PhD, was first author.

Citation
Activity-dependent regulation of GABAergic synapse development by Npas4.
Lin Y; et al.
Nature Sep 24, 2008 [advance online publication.
The article can be viewed at http://dx.doi.org/10.1038/nature07319.

Children's Hospital Boston is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 500 scientists, including eight members of the National Academy of Sciences, 11 members of the Institute of Medicine and 12 members of the Howard Hughes Medical Institute comprise Children's research community. Founded as a 20-bed hospital for children, Children's Hospital Boston today is a 397-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Children's also is the primary pediatric teaching affiliate of Harvard Medical School.

Children's Hospital Boston


Study Finds People With Fragile X, Carriers Likely To Have Additional Conditions

People with fragile X syndrome, as well as those who carry the gene, are likely to have additional conditions that include attention problems and anxiety, according to a study by researchers at RTI International.

The study, published in the Aug. 15 issue of American Journal of Medical Genetics, surveyed more than 1,000 parents of children who either had fragile X syndrome, the most common inherited cause of intellectual disability, or were a carrier of the disease.

In this first large-scale assessment of conditions associated with fragile X syndrome, researchers found that most boys and many girls with the syndrome experience attention problems, anxiety and hyperactivity, in addition to developmental delay, 85 percent of males and 44 percent of females experienced two or more additional conditions.

Additionally, the study showed that carriers, those who have the altered gene but generally do not show signs of the disease, also had an increased prevalence of co-occurring conditions. Boys who carried the gene were more likely than typical children to have been diagnosed or treated for developmental delay, attention problems, aggression, seizures, autism, and anxiety.

Girls who carried the gene were more likely than typical children to have been diagnosed or treated for attention problems, anxiety, depression, and developmental delay.

"This study provides new insights into what it means to be a carrier of fragile X syndrome," said Don Bailey, Ph.D., a Distinguished Fellow at RTI and director of the project that produced this research. "Obviously carriers who are parents experience many challenges in raising a child with fragile X. This study suggests the possibility that carriers of fragile X may also have a higher biological susceptibility to things like anxiety or attention problems."

The number of co-occurring conditions children experienced was strongly associated with parent reports of the child's ability to learn, adaptability and quality of life. The findings suggest that clinicians should be sure to assess both carriers and individuals affected by fragile X to determine whether they have any of these co-occurring conditions so that they can be treated.

Fragile X syndrome is caused by the disruption of a single gene that leads to a protein needed for normal brain development. Changes in the gene are passed down from one generation to the next, usually silently in individuals who are not aware that they carry the disrupted gene. In each generation, the risk for having an affected child increases.

The study was funded by a grant from the Centers for Disease Control & Prevention.

About RTI International

RTI International is one of the world's leading research institutes, dedicated to improving the human condition by turning knowledge into practice. Our more than 3,800 professionals provide research and technical services to governments and businesses in more than 40 countries in the areas of health and pharmaceuticals, education and training, surveys and statistics, advanced technology, international development, economic and social policy, energy, and the environment. For more information, visit http://www.rti.org.

American Journal of Medical Genetics

Major News Of The Day


9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

9/25/2008

 

 

 

 

 

 

What the heck is DRM, and why is it so bad?

Q: Who are you and why are you doing this?
A: We're technologist, programmers, computer users, and we're aware of these threats. It falls to us to bring this issue to the attention of the public.

Q: What are you going do about it?
A: I was just going to ask you that! But lets carry on this conversation after you've signed up. Join us now.

 

September: 1 , 2 , 3 , 4 , 5 , 6&7 , 8 , 9 , 10 , 11 , 12 , 13&14 , 15 , 16 , 17 , 18 , 19 , 20&21 , 22 , 23 , 24

August: 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10, 11 , 12 , 13 , 14 , 15 , 16&17 , 18 , 19 , 20 , 21 , 22 , 23&24 , 25 , 26 , 27 , 28 , 29 , 30&31

July 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 , 17, 18, 19-20, 21, 22, , 23, 24, 25, 26-27, 28 , 29 , 30, 31

June: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21and22,

23, 24, 25, 26, 27,28, 29, 30

MTV Video Music ;

Sources Of News:

Consumer Report

Seattle Times http://seattletimes.nwsource.com/html/health/

Medical News Today http://www.medicalnewstoday.com/ Washington Post http://www.washingtonpost.com/
Reuters Health http://www.reuters.com/news/health'type=healthNews Associated Press http://www.ap.org/
Daily Mail http://www.dailymail.co.uk/pages/live/ CDC http://www.cdc.gov/
Telegraph BankRate.com http://bankrate.com/
Newswise http://www.newswise.com/ BBC

The New England Journal of Medicine (NEJM) http://content.nejm.org/

Iconocast is about learning and teaching without borders; Home Page ; Contact ; info@liveinfospace.com